Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:34 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Navitoclax and Vistusertib in Treating Patients With Relapsed Small Cell Lung Cancer and Other Solid Tumors
NCT03366103 · National Cancer Institute (NCI) · PHASE1/PHASE2 · terminated · last registry update 2023-10-17 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Drug supply issues” | – | Registry record, National Cancer Institute (NCI) |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against BCL2 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2024-10-15Phase 3 first posted: Ascentage Pharma Group Inc., Lisaftoclax (APG-2575) + Azacitidine Injection (NCT06641414)
- 2024-05-24Phase 3 first posted: AbbVie, Venetoclax + Acalabrutinib (NCT06428019)
- 2024-04-23Results posted on the registry: Dana-Farber Cancer Institute, IBRUTINIB + Venetoclax (NCT04273139)
- 2024-03-20Phase 3 first posted: Ascentage Pharma Group Inc., Lisaftoclax (APG-2575) + Acalabrutinib (NCT06319456)
- 2023-10-27Phase 3 first posted: Ascentage Pharma Group Inc., lisaftoclax +BTK inhibitor + BTK inhibitor (NCT06104566)
- 2023-10-10Phase 3 first posted: BeOne Medicines, Sonrotoclax + Zanubrutinib (NCT06073821)
- 2023-10-10Phase 3 first posted: The Second Affiliated Hospital of Kunming Medical University, a drug against BCL2 (NCT06073730)
- 2023-09-18Results posted on the registry: Takeda, Pevonedistat + Venetoclax (NCT04266795)
- 2023-07-17Phase 3 first posted: Merck Sharp & Dohme LLC, Nemtabrutinib + Venetoclax (NCT05947851)
- 2023-07-11Phase 3 first posted: The First Affiliated Hospital of Soochow University, Venetoclax Oral Tablet + Daunorubicin (NCT05939180)
- 2023-06-22Results posted on the registry: City of Hope Medical Center, Romidepsin + Venetoclax (NCT03534180)
- 2023-01-27Results posted on the registry: AbbVie, Azacitidine + Venetoclax (NCT02993523)
- 2022-12-16Phase 3 first posted: The First Affiliated Hospital of Soochow University, Azacitidine Combined With Venetoclax and ATRA group (NCT05654194)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision